Time course of recovery of health status following an infective exacerbation of chronic bronchitis.
about
Inhaled corticosteroids versus long-acting beta2-agonists for chronic obstructive pulmonary diseaseInhaled corticosteroids versus long-acting beta 2 -agonists for chronic obstructive pulmonary diseasePulmonary rehabilitation following exacerbations of chronic obstructive pulmonary diseasePulmonary rehabilitation following exacerbations of chronic obstructive pulmonary diseaseInhaled corticosteroids versus long acting beta-agonists for chronic obstructive pulmonary diseaseAntibiotic activity of telithromycin and comparators against bacterial pathogens isolated from 3,043 patients with acute exacerbation of chronic bronchitisRespiratory rehabilitation after acute exacerbation of COPD may reduce risk for readmission and mortality -- a systematic reviewExacerbations of COPDMechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary diseasePulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease.COPD exacerbations. 4: PreventionRehabilitation of Discharged Patients With Chronic Obstructive Pulmonary Disease-Are New Strategies Needed?Tiotropium's cost-effectiveness for the treatment of COPD: a cost-utility analysis under real-world conditions.Greatest International ANtiinfective Trial (GIANT) with moxifloxacin in the treatment of acute exacerbation of chronic bronchitis: subanalysis of Chinese data of a global, multicenter, noninterventional study.Antibiotic treatment of exacerbations of COPD in general practice: long-term impact on health-related quality of lifePhysical activity, health status and risk of hospitalization in patients with severe chronic obstructive pulmonary diseaseNon-invasive ventilation (NIV) as an aid to rehabilitation in acute respiratory disease.Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation.25-hydroxyvitamin D deficiency, exacerbation frequency and human rhinovirus exacerbations in chronic obstructive pulmonary disease.Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis: a prospective, multicenter, observational study (AVANTI)A genetic variant of p53 restricts the mucous secretory phenotype by regulating SPDEF and Bcl-2 expression.The concept of control of COPD in clinical practice.Longitudinal change in quality of life following hospitalisation for acute exacerbations of COPDHealth status in the TORCH study of COPD: treatment efficacy and other determinants of change.Role of clinical questionnaires in optimizing everyday care of chronic obstructive pulmonary disease.Risk of nonlower respiratory serious adverse events following COPD exacerbations in the 4-year UPLIFT® trial.Efficiency and safety of pulmonary rehabilitation in acute exacerbation of chronic obstructive pulmonary disease.Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study.Assessment of progression of COPD: report of a workshop held in Leuven, 11-12 March 2004Effect of treatments on the progression of COPD: report of a workshop held in Leuven, 11-12 March 2004.Prognostic factors for clinical failure of exacerbations in elderly outpatients with moderate-to-severe COPD.Using the Electronic Nose to Identify Airway Infection during COPD Exacerbations.Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain.Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results.Measurement of physiological recovery from exacerbation of chronic obstructive pulmonary disease using within-breath forced oscillometry.COPD exacerbations .1: Epidemiology.Exacerbation frequency and course of COPD.Role of infection and antimicrobial therapy in acute exacerbations of chronic obstructive pulmonary disease.Association between antibiotic treatment and outcomes in patients hospitalized with acute exacerbation of COPD treated with systemic steroidsDeterminants of bacteriological outcomes in exacerbations of chronic obstructive pulmonary disease.
P2860
Q24234164-D07762BB-6CA2-4C63-9514-E1DC2E1521A3Q24236037-0F0C41F9-0A19-4E5E-8722-1FBFD41A0B39Q24236241-1C356312-D464-4ABB-A752-178B000BFD06Q24241029-C4DF0EA2-8C69-4CAB-B118-EF1924562FDAQ24243419-A1BC9AC8-01C4-4631-BA6B-FAD4C5AC27D6Q24803536-97C430C3-4D23-4269-83E9-5C7C08023239Q24814417-2BC256E7-5B4A-4BEC-866D-689F77C22471Q26764891-08DBC4A7-80C2-4F6D-96EE-D218AD8F02B6Q27000043-7F67724C-5681-4415-9128-399EEF75C4ABQ30240148-0848A975-58C2-4644-A58D-94EFF82A0018Q30480789-3E32E647-FF8C-42FB-9BB8-EBD815D055E7Q33633132-8C6A40C4-9458-46A0-8B9A-54413E3BB6CEQ33693222-C22177AE-09E8-4C98-ADE9-3F791F8EE4CAQ33701662-D490F93F-2BC3-4C5B-AB45-989513DD9FD0Q33755801-64A13AAC-0556-472C-A69D-2DDD467D91FAQ33928124-F251BEA8-A8B0-4787-9070-7CD130026BB6Q34104149-3C499114-10DA-4132-97C8-6F382DAF84B8Q34202072-4483D3F4-9BD3-4A65-BE12-C406D932F18EQ34315062-58F722F6-B40F-48BA-99E2-FAD7A13A68DEQ34560033-E628B1FA-D65F-4A00-9905-FC1CF93D5394Q34584528-20B69012-44B5-45BF-9E8A-7233CAD31DF6Q34742591-218710D8-F525-428A-AB69-3D2D6F011732Q35008199-5A084BF0-F5EE-42E6-B747-8712C41246DDQ35052737-C5ED6621-7A26-4E3E-8010-33084AD02E05Q35056993-0341FD6E-812C-4ABA-83EA-E18CCBBE7697Q35120004-373E0E45-FE7D-467B-9589-21140A555B6AQ35218908-F1934ED5-7892-4650-9861-EBC17030CBA1Q35536623-CBAD13B1-39CC-4C2D-ADD1-8B44DF5BB212Q35537594-02FF0D0F-400E-4C3B-A0CF-D88EB3427206Q35537629-DF653EFF-DDDA-407C-8793-3863253D3F05Q35694431-7E5CAF55-AED2-4D55-A42D-3B106862967BQ35768180-9767F944-7CF5-4D77-B428-4D4E0C14D15BQ35878722-088D83BE-6A49-4F70-A254-637F88D7B115Q36087058-79BEA0DD-A483-439F-8FBA-74936EA5381FQ36166290-2F2DC773-2477-4688-A3F4-1F3D04A23BECQ36183861-E9921449-B49B-410A-BB72-D1CF5FD49787Q36283928-315E55EF-8CA7-4B51-BB24-97E3D2DDA8D7Q36379352-B7E7050E-2444-4B1B-AE6E-65493FB70A63Q36510098-CB0C60EE-8335-47E3-821B-85C82953769BQ36526951-C493FF15-AFAC-4AFB-B743-AEB027F68A80
P2860
Time course of recovery of health status following an infective exacerbation of chronic bronchitis.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Time course of recovery of hea ...... rbation of chronic bronchitis.
@ast
Time course of recovery of hea ...... rbation of chronic bronchitis.
@en
type
label
Time course of recovery of hea ...... rbation of chronic bronchitis.
@ast
Time course of recovery of hea ...... rbation of chronic bronchitis.
@en
prefLabel
Time course of recovery of hea ...... rbation of chronic bronchitis.
@ast
Time course of recovery of hea ...... rbation of chronic bronchitis.
@en
P2860
P356
P1433
P1476
Time course of recovery of hea ...... rbation of chronic bronchitis.
@en
P2093
GLOBE Study Group
P2860
P304
P356
10.1136/THORAX.58.7.589
P407
P577
2003-07-01T00:00:00Z